- Home
- MTR vs GTBP Comparison
MTR vs GTBP Comparison
Compare MTR & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTR | GTBP |
|---|---|---|
| Founded | 1979 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 8.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MTR | GTBP |
|---|---|---|
| Price | $4.30 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.2K | ★ 2.4M |
| Earning Date | 04-02-2026 | 02-20-2026 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $623,288.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.03 | $0.54 |
| 52 Week High | $10.42 | $3.85 |
Technical Indicators
Market Signals| Indicator | MTR | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 51.68 |
| Support Level | $4.20 | $0.65 |
| Resistance Level | $4.87 | $0.75 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 33.92 | 42.81 |
Price Performance
Historical ComparisonAbout MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.